Viktoria Blumenberg

Klinikum der Universität München

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (15)

Collaborators (9)

Julio Vera

Full Professor (W2)

Universitätsklinikum Erlangen

Gerhard Krönke

Wolfgang G. Kunz

University Hospital

Eva Hoster

University Hospital, LMU Munich

Simon Völkl

Robert Jenq

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

Marion Subklewe

LMU University Hospital

Konstantin Hellwig

University of Erlangen-Nuremberg

Matthias Alexander Fante

University Hospital Regensburg

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Viktoria Blumenberg

Research Interests

Explore related searches

Contact this professor

Articles (15)

Collaborators (9)

Julio Vera

Gerhard Krönke

Wolfgang G. Kunz

Eva Hoster

Simon Völkl

Robert Jenq

Marion Subklewe

Konstantin Hellwig

Matthias Alexander Fante

Make your next move.

Viktoria Blumenberg

Research Interests

Explore related searches

Contact this professor

Articles (15)

Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy

Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteria

A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy

Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL

Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy

Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy

Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL

Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy

Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion

Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use

Cellular and humoral immune responses to SARS-CoV-2 vaccination in patients after CD19.CAR-T cell therapy.

Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL

A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma

Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall Survival

Collaborators (9)

Julio Vera

Gerhard Krönke

Wolfgang G. Kunz

Eva Hoster

Simon Völkl

Robert Jenq

Marion Subklewe

Konstantin Hellwig

Matthias Alexander Fante

Make your next move.